论文部分内容阅读
本文观察普瑞博思对慢性消化不良的治疗效果。选择曾用胃复安或吗叮啉治疗2～4周无效的慢性消化不良病人173例；随机分为两组：普瑞博恩组91例，服用普瑞博恩5mg，每日3次；雷尼替丁组82例，服用雷尼替丁150mg，每日2次。两组疗程均为4周。分别观察第2及第4周消化道症状变化及不良反应。结果表明，普瑞博恩组总有效率95．6％，出现不良反应占16．5％，多数能耐受。雷尼替丁组总有效率43．9％，两组总有效率相比具有非常显著差异（P＜0．001）。提示：普瑞博思对用胃复安或吗叮啉治疗无效的慢性消化不良有显著疗效，是一种安全而有效的胃肠道促动力药。
This article observes Puri Bose treatment of chronic dyspepsia. 173 patients with chronic dyspepsia who had been treated with metoclopramide or domperidone 2 to 4 weeks were randomly divided into two groups: 91 patients in the Prednisone group and 5 mg Prednisolone 3 times daily. Ranitidine group of 82 patients, taking ranitidine 150mg, 2 times a day. Two courses of treatment were 4 weeks. The changes of gastrointestinal symptoms and adverse reactions in the second and fourth weeks were observed. The results showed that the total effective rate was 95.6%, adverse reactions accounted for 16.5%, most can tolerate. The total effective rate in ranitidine group was 43.9%, with significant difference (P <0.001) between the two groups. Prompt: Pregabalin has a significant efficacy against chronic dyspepsia with metoclopramide or doramectin, and is a safe and effective gastrointestinal motility vehicle.